Centrus Energy Corp. enters its May 7 earnings call in a paradoxical position: short sellers have held one of the largest positions in the nuclear fuel space for months, yet those same bears have been quietly trimming exposure even as the stock rallied 12% over the past month to $206.04.
The short interest story at Centrus is the dominant data thread, and it cuts two ways. Bears remain heavily committed — 24% of the free float is sold short — but the trend has clearly turned against them. SI % FF has fallen from roughly 25.4% in late March to 22.9% now, a steady unwind of nearly two and a half percentage points over six weeks. The most aggressive retreat came in early April, when SI dropped sharply from around 24.9% to 23.3% in a single week, coinciding with broader market volatility that likely forced some position reductions. The FINRA fortnightly report put official short shares at 4.3 million with 5.8 days to cover — a meaningful liquidity overhang for a stock that doesn't trade enormous volume.
The lending market tells an even tighter story. Availability has collapsed to near-zero: the borrow pool is almost entirely deployed, with availability touching 99% utilisation for the second time in two weeks (it hit 100% three times in April alone). Every share in the lending pool is effectively spoken for. That scarcity has not translated into a cost-to-borrow spike — the rate is running at 0.84% annualised, a fraction of what genuinely distressed borrow looks like. That disconnect matters: it suggests the tight borrow is structural, reflecting a fixed pool of lendable shares rather than an acute short squeeze dynamic. Options positioning corroborates the cautious mood without amplifying it — the put/call ratio is 0.73, modestly above its 20-day average of 0.70 and just over one standard deviation elevated. Defensive hedging is ticking higher, but it is not at an extreme.
The Street is split, but leans cautious. B. Riley trimmed its target from $315 to $295 on April 24 while holding its Buy rating — the most recent analyst action, and one that acknowledges Centrus's direction of travel while pulling in near-term expectations. JP Morgan, Citi, and UBS have all cut targets in prior months, each holding Neutral. Needham stays at $357 with a Buy. The consensus price target of $269 sits 31% above the current price, implying the Street sees genuine recovery potential, though the cluster of Neutral ratings from major firms reflects real uncertainty about the timing. The bear case centres on earnings visibility: Q1 adj. EPS came in at $1.05, down sharply from $1.68 a year earlier, even as revenue grew modestly to $76.7 million. The bull case got a fresh boost from management raising full-year 2026 revenue guidance to $450–$500 million, up from $425–$475 million — and from the announcement of a joint-venture exploration with Oklo for HALEU deconversion services, extending Centrus's strategic reach in advanced reactor fuel. The PE multiple at 51.8x and EV/EBITDA at 50.3x signal the market is paying for a growth story that has yet to fully materialise in near-term earnings. The ORTEX short score of 73 — ranked in the 2nd percentile of the universe — confirms this is one of the more structurally shorted names across all sectors.
Institutional ownership provides some ballast. BlackRock added 173,000 shares in the latest reporting period and now holds 7.5% of the company. State Street added 410,000 shares and Mirae Asset added 185,000 — meaningful buying from passive and active managers alike into the recent weakness. Against that, insider activity since March has been routine: a CMO award-and-sell in March totalling around $175,000, and small SVP sells in April. The net insider position over 90 days is a marginal $250,000 of net selling — insignificant relative to the institutional flows moving in the other direction.
The earnings history adds important context. The February 11 Q4 print sent the stock down 30% the next day and 22% over the following week — the company's most damaging post-earnings reaction in recent memory. That miss reset price expectations and is the primary reason so many analysts have been trimming targets since. The Q1 beat on revenue and the guidance raise suggest management is working to stabilise the narrative, but the stock's proximity to levels where multiple analysts hold Neutral ratings means the path from here depends heavily on whether the Oklo partnership and HALEU progress can be quantified into forward earnings estimates.
The next print lands May 7. What to watch is whether guidance specificity on the DOE $900 million award and HALEU production timeline is enough to loosen the grip of the bears holding a quarter of the float — or whether a repeat of February's disappointment prompts the next leg of the short squeeze that the tight borrow pool is already theoretically primed for.
See the live data behind this article on ORTEX.
Open LEU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
